Rituximab: all 1,386 studies that test it
Page 10 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary CirrhosisCompletedNCT02376335Phase 2
- Treatment -Resistant Neovascular Age-Related Macular DegenerationCompletedNCT02332941Phase 1
- Maintenance Treatment Versus Observation in Elderly Patients With PCNS LymphomaStatus unknownNCT02313389Phase 3
- Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)CompletedNCT02304354Phase 3
- Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)CompletedNCT02303119Phase 3
- Synergetic B-cell Immodulation in SLECompletedNCT02284984Phase 2
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTStatus unknownNCT02267915Phase 2
- A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis PatientsCompletedNCT02253264Phase 1
- Rituximab in Interstitial PneumonitisCompletedNCT02251964Phase 2/3
- Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
- B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.CompletedNCT02229942Phase 3
- Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasWithdrawnNCT02228512Phase 1/2
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.CompletedNCT02206308Phase 1
- Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
- Low-dose Glucocorticoid Vasculitis Induction StudyStatus unknownNCT02198248Phase 4
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
- Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus RituximabCompletedNCT02157181Phase 2
- Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant MelanomaStatus unknownNCT02142335Phase 2
- A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）WithdrawnNCT02137681Phase 3
- A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisCompletedNCT02115997Phase 4
- Rituximab and DexaBEAM as Salvage Therapy for Relapsed LymphomaCompletedNCT02099292Phase 2
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular LymphomaCompletedNCT02063685Phase 3
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT02049541Phase 1
- Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and ImmunochemotherapyCompletedNCT02042391Phase 2
- Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIbCompletedNCT02012088Phase 2
- Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaActive, not recruitingNCT02007044Phase 2
- Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FILStatus unknownNCT01990144Phase 2
- Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe PemphigusStatus unknownNCT01974518Phase 3
- Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System LymphomaCompletedNCT01956695Phase 2
- Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous NephropathyCompletedNCT01955187Phase 3
- Rituximab + GM-CSF in Patients With Follicular B-Cell LymphomaCompletedNCT01939730Phase 2
- Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaStatus unknownNCT01933711Phase 3
- GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01933516Phase 1
- An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaTerminatedNCT01902862Phase 2
- Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
- Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT01880567Phase 2
- Long-Term Efficacy and Safety of CT-P10 in Patients With RACompletedNCT01873443Phase 1
- Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)CompletedNCT01868269Phase 3
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCLCompletedNCT01865110Phase 3
- Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDCompletedNCT01862926Phase 2/3
- Treatment for Advanced B-Cell LymphomaCompletedNCT01859819Phase 2
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Rituximab for Anti-cytokine Autoantibody-Associated DiseasesCompletedNCT01842386Phase 1
- BR in Patients With CLL With Comorbidities and/or Renal DysfunctionCompletedNCT01832922Phase 1
- Lenalidomide Plus Rituximab (R) in Non Follicular NHLStatus unknownNCT01830478Phase 2
- VELCADE® Plus Rituximab in Non Hodgkin's Follicular LymphomaCompletedNCT01830465Phase 2
- Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase TherapyActive, not recruitingNCT01829958Not applicable
- Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT01829568Phase 1
- T&B Depletion Non MalignantStatus unknownNCT01810926Phase 2
- Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)CompletedNCT01808911Phase 3
- Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT LymphomaActive, not recruitingNCT01808599Phase 2
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaCompletedNCT01788020Phase 3
- Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaCompletedNCT01775631Phase 1
- Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus NephritisTerminatedNCT01773616Phase 3
- Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus NephropathyTerminatedNCT01765842Phase 3
- Study of Sonographic Efficacy of Rituximab in Rheumatoid ArthritisCompletedNCT01765374Phase 4
- Dose Adjusted EPOCH-R, to Treat Mature B Cell MalignanciesCompletedNCT01760226Early Phase 1
- Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid ArthritisCompletedNCT01759030Phase 3
- Rituximab in Systemic SclerosisCompletedNCT01748084Phase 2/3
- Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01744626Phase 1
- Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLCompletedNCT01737177Phase 2
- Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisCompletedNCT01731561Phase 3
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
- Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01729104Phase 1
- Low-dose Rituximab Regimens in Chinese Adult Patients With Immune ThrombocytopeniaCompletedNCT01719692Not applicable
- Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple SclerosisCompletedNCT01719159Phase 2
- Rituximab Trial for Pediatric Nephrotic SyndromeStatus unknownNCT01716442Phase 2/3
- Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT01713738Phase 1/2
- Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLEWithdrawnNCT01702038Phase 2
- Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaCompletedNCT01701232Phase 3
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
- Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell LymphomaCompletedNCT01686321Phase 2
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01682616Phase 1
- A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01671904Phase 1
- A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)CompletedNCT01650727Phase 1
- A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular LymphomaCompletedNCT01650701Phase 3
- Phase 1b Safety and Efficacy Study of TRU-016TerminatedNCT01644253Phase 1
- A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of ActionCompletedNCT01638715Phase 4
- Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction ImmunochemotherapyTerminatedNCT01625741Phase 2
- Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell LymphomaCompletedNCT01622439Phase 1/2
- A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01594229Phase 1
- Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid ArthritisCompletedNCT01593332Phase 4
- The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's LymphomasCompletedNCT01567475Phase 1
- Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseCompletedNCT01562990Phase 1/2
- Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLCompletedNCT01562977Phase 2
- Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell LymphomaCompletedNCT01560117Phase 2
- A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01558167Phase 1/2
- Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular LymphomaCompletedNCT01542918Phase 1
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell LymphomaWithdrawnNCT01539174Phase 2
- Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive LymphomasCompletedNCT01538641Phase 2
- Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialTerminatedNCT01534949Phase 1
- Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid ArthritisCompletedNCT01534884Phase 1
- Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular LymphomaCompletedNCT01523860Phase 2
- Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation TreatmentStatus unknownNCT01521689Phase 2
- Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsCompletedNCT01516580Phase 3